Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
G. D'Haens,S. V. van Deventer,7 Authors,P. Rutgeerts
1999 · DOI: 10.1016/S0016-5085(99)70005-3
Gastroenterology · 772 Citations
TLDR
Clinical improvement after infliximab therapy in active Crohn's disease is accompanied by significant healing of endoscopic lesions and disappearance of the mucosal inflammatory infiltrate and architectural changes persisted in most patients.